[Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications]

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are vital targeted cancer therapies.
• TKIs are associated with a 5-25% incidence of liver adverse events, potentially severe.
• Managing TKI-induced liver injury is essential for balancing treatment benefits and patient safety.

Purpose of the Study:

• To review the mechanisms of idiosyncratic hepatotoxicity induced by TKIs.
• To discuss the role of reactive metabolites, drug characteristics, and patient factors (including genetics) in TKI liver injury.
• To outline strategies for preventing and managing TKI-related liver injury and monitoring recommendations.

Main Methods:

• Literature review focusing on TKI hepatotoxicity mechanisms.
• Analysis of drug-specific characteristics and patient risk factors.
• Synthesis of current strategies for prevention and management.

Main Results:

• Hepatotoxicity arises from idiosyncratic reactions involving reactive metabolites.
• Drug properties and patient genetic factors significantly influence TKI liver injury risk.
• Understanding these mechanisms informs preventative and therapeutic strategies.

Conclusions:

• Effective management of TKI therapy requires awareness of potential liver injury.
• Personalized monitoring strategies based on TKI type are recommended.
• Further research into genetic predispositions can optimize patient care.